BioEclipse Therapeutics, a South San Francisco-based clinical-stage biopharmaceutical company, raised $7.7m in Series A-1 financing.
The round, which brought total funding raised to date to $9.3m, was led by Revelis Capital Group, with participation from Tsingyuan Ventures, DEFTA Partners, TSVC (TEEC Angel Fund) and Plum Alley.
The company intends to use the funds to advance lead immunotherapy, CRX-100, into Phase 1b/2a clinical trials in therapy-refractory solid tumors.
Led by Pamela Contag, Ph.D., founder and CEO, BioEclipse Therapeutics is a clinical-stage biopharmaceutical company committed to delivering curative immuno-oncology therapeutics to patients with cancer. The company is preparing to initiate Phase 1b/2a clinical trials with, CRX-100, a patented, first in class, intravenously delivered, targeted immunotherapy against solid tumors. CRX-100, is being developed to deliver potentially curative treatment to patients over a broad range of tumor types, including some rare pediatric cancers.
BioEclipse also announced the addition of three new board members:
– Mark Frohlich, MD, former Executive Vice President at Juno Therapeutics;
– Elona Baum, Managing Director of DEFTA Partners; and
– Oliver Hopkinson, Co-Founder and Manager of Revelis Capital Group.